• Home
  • News & Events
    • News Releases
    • Events & Presentations
    • Publications
  • Corporate Governance
    • Leadership
    • Board of Directors
    • Governance Documents
    • Committee Composition
  • Financial Information
    • SEC Filings
    • Annual Report and Proxy
  • Stock Information
  • Resources
    • Email Alerts
    • Contact

Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Oct 3, 2024 | Press Releases

CINCINATTI, OH., Oct. 03, 2024 — In a release issued under the same headline earlier today by Onconetix, Inc. (Nasdaq: ONCO), please note that in the first paragraph of the release, the name of the financial advisor to Onconetix in the transaction had been...

Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Oct 3, 2024 | Press Releases

CINCINATTI, Oh., Oct. 03, 2024 — Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or “the Company”) (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development and commercialization of...

Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Oct 3, 2024 | Press Releases

CINCINATTI, Oh., Oct. 03, 2024 — Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or “the Company”) (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development and commercialization of...

Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders

Sep 20, 2024 | Press Releases

CINCINNATI, Ohio, Sept. 20, 2024 — Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s...

Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders

Sep 20, 2024 | Press Releases

CINCINNATI, Ohio, Sept. 20, 2024 — Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s...

Onconetix Announces Closing of Warrant Exercise for $1.11 Million Gross Proceeds

Jul 15, 2024 | Press Releases

CINCINNATI, July 15, 2024 — Onconetix, Inc. (“Onconetix” or the “Company”) (Nasdaq: ONCO), today announced the closing of the previously announced exercise of certain existing warrants to purchase 7,458,642 shares of its common stock...
« Older Entries
Next Entries »

Recent Posts

  • Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
  • Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.
  • Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort
  • Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress
  • Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing

Recent Comments

No comments to show.

Stay up to date

Keep informed on investor news & updates

© 2025 Onconetix